C12N2820/55

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS
20250146015 · 2025-05-08 · ·

The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element, but include at least a portion of a bacterial origin of replication.

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS
20250146016 · 2025-05-08 · ·

The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element, but include at least a portion of a bacterial origin of replication.

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS
20250179517 · 2025-06-05 · ·

The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element, but include at least a portion of a bacterial origin of replication.

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS
20250188487 · 2025-06-12 · ·

The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element, but include at least a portion of a bacterial origin of replication.

Phagemid vector

The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.

COMPOSITIONS AND METHODS FOR RECOMBINANT AAV PRODUCTION

Provided herein are recombinant polynucleotides encoding helper functions and helper plasmids suitable for use in the production of recombinant AAV particles. Also provided herein are methods for producing rAAV particles.

Single-vector Type I vectors

The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.

Expression vectors for eukaryotic expression systems

The invention provides expression vectors for expressing recombinant proteins (e.g., biologics) in mammalian cells. Also provided are host cells comprising the expression vectors, methods of producing the recombinant proteins, and methods of propagating the expression vectors.

EXPRESSION AND SECRETION SYSTEM
20250333723 · 2025-10-30 ·

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.

Non-immunogenic circular, non-viral DNA vectors
12473567 · 2025-11-18 · ·

The present disclosure relates to circular, non-viral DNA vectors, compositions including one or more of the disclosed vectors, and methods for delivering and/or expressing one or more therapeutic genes (e.g., proteins) in mammals, e.g., human patients. In some embodiments, the present disclosure is directed to circular, non-viral DNA vectors, such as circular non-viral DNA vectors including at least two inverted repeat sequences, where the at least two inverted repeat sequences are separated by a non-repeated nucleotide sequence which is not part of the at least two inverted repeat sequences. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element. In some embodiments, the disclosed circular, non-viral DNA vectors do not include a DD element, but include at least a portion of a bacterial origin of replication.